WARRINGTON, PA — Windtree Therapeutics, Inc. (OTCID: WINT) has strengthened its intellectual property position with newly allowed and granted patents in Canada, Mexico, and Israel, reinforcing the company’s long-term strategy to advance novel therapies for acute heart failure and related cardiovascular conditions.
The company announced that patents covering istaroxime — its lead dual-mechanism therapy for acute heart failure — have been allowed in Canada and Mexico. In addition, Israel has granted a patent for Windtree’s next-generation pure SERCA2a activator, a therapeutic class designed to improve cardiac function through enhanced calcium regulation.
With these additions, Windtree now holds 59 issued or allowed patents and 17 pending across its cardiovascular portfolio. The estate includes protections for istaroxime, dual-mechanism SERCA2a activators, and pure SERCA2a activators targeting acute heart failure, arrhythmia prevention, and cardiogenic shock.
Heart failure remains a global health challenge, affecting more than 60 million people worldwide. Roughly 20 million patients are hospitalized each year for acute episodes, including 1.5 million in the United States alone. Patients with low systolic blood pressure are at particularly high risk, facing double-digit mortality rates at admission and again within six months. Limited treatment options — often hampered by renal side effects and unwanted arrhythmias — underscore the need for new therapeutic approaches.
Windtree CEO Jed Latkin said the newly secured patent protections help advance the company’s strategy to position istaroxime as a differentiated treatment option. “We believe that istaroxime has a unique profile to effectively treat acute heart failure patients with low blood pressure, who are most in need,” Latkin said. He noted that clinical data show the therapy can improve cardiac function and blood pressure without increasing heart rate or triggering significant arrhythmias — an advantage over many standard treatments.
Istaroxime is a first-in-class, dual-action agent that enhances both contraction and relaxation of the heart by inhibiting the Na+/K+-ATPase pump and activating the SERCA2a calcium pump. Phase 2 studies have demonstrated improvements in cardiac performance and hemodynamics without the safety trade-offs common among other inotropic drugs.
Windtree’s pure SERCA2a activators represent the next stage of development, with preclinical candidates in both oral and intravenous formulations. These compounds specifically target the SERCA2a mechanism with the goal of offering new therapies for heart failure and related conditions.
The company is actively pursuing development partnerships and continues to evaluate Phase 3 readiness for istaroxime based on encouraging clinical results to date.
With its latest international patent wins, Windtree is adding depth and durability to a cardiovascular pipeline aimed at addressing persistent gaps in heart failure treatment — an area where demand for innovation continues to intensify.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.